StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) stock

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026Score 9/3079% below fair value
$1.78−0.01 (-0.56%)

Close on Nov 13, 2026Market cap $19.34MP/E –Yield –

Aytu BioPharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Aytu BioPharma's ebitda for the twelve months ending Jun 30, 2026 was -$4.39M. For fiscal 2026 it was -$4.39M. The highest annual figure on record is $5.13M in fiscal 2024.

Annual ebitda

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$4.39M–
FY2025Jun 30, 2025-$2.45M-147.7%
FY2024Jun 30, 2024$5.13M–
FY2023Jun 30, 2023-$8.25M–
FY2022Jun 30, 2022-$99.76M–
FY2021Jun 30, 2021-$49.67M–
FY2020Jun 30, 2020-$15.42M–
FY2019Jun 30, 2019-$14.12M–
FY2018Jun 30, 2018-$17.11M–
FY2017Jun 30, 2017-$15.76M–
FY2016Jun 30, 2016-$20.83M–
FY2015Jun 30, 2015-$7.51M-126664.2%
FY2013Aug 31, 2013$5.94K–
FY2012Aug 31, 2012-$2.95K–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026$344.00K–
Q3 FY2026CQ1 2026Mar 31, 2026-$2.94M-179.4%
Q2 FY2026CQ4 2025Dec 31, 2025-$1.09M–
Q1 FY2026CQ3 2025Sep 30, 2025-$701.00K-273.5%
Q4 FY2025CQ2 2025Jun 30, 2025-$6.16M–
Q3 FY2025CQ1 2025Mar 31, 2025$3.71M+1464.6%
Q2 FY2025CQ4 2024Dec 31, 2024-$403.00K-108.0%
Q1 FY2025CQ3 2024Sep 30, 2024$404.00K-70.4%
Q4 FY2024CQ2 2024Jun 30, 2024-$715.00K-131.3%
Q3 FY2024CQ1 2024Mar 31, 2024$237.00K–
Q2 FY2024CQ4 2023Dec 31, 2023$5.05M–
Q1 FY2024CQ3 2023Sep 30, 2023$1.36M+176.5%
Q4 FY2023CQ2 2023Jun 30, 2023$2.29M–
Q3 FY2023CQ1 2023Mar 31, 2023-$6.72M–
Q2 FY2023CQ4 2022Dec 31, 2022-$5.02M–
Q1 FY2023CQ3 2022Sep 30, 2022$493.00K–
Q4 FY2022CQ2 2022Jun 30, 2022-$14.72M–
Q3 FY2022CQ1 2022Mar 31, 2022-$50.85M–
Q2 FY2022CQ4 2021Dec 31, 2021-$8.62M–
Q1 FY2022CQ3 2021Sep 30, 2021-$25.02M–
Q4 FY2021CQ2 2021Jun 30, 2021-$20.75M–
Q3 FY2021CQ1 2021Mar 31, 2021-$25.60M–
Q2 FY2021CQ4 2020Dec 31, 2020-$5.56M–
Q1 FY2021CQ3 2020Sep 30, 2020-$1.52M–
Q4 FY2020CQ2 2020Jun 30, 2020-$4.70M–
Q3 FY2020CQ1 2020Mar 31, 2020-$4.77M–
Q2 FY2020CQ4 2019Dec 31, 2019-$4.95M–
Q1 FY2020CQ3 2019Sep 30, 2019-$3.87M–
Q4 FY2019CQ2 2019Jun 30, 2019-$3.83M–
Q3 FY2019CQ1 2019Mar 31, 2019-$4.27M–
Q2 FY2019CQ4 2018Dec 31, 2018-$4.53M–
Q1 FY2019CQ3 2018Sep 30, 2018-$2.86M–
Q4 FY2018CQ2 2018Jun 30, 2018-$3.21M–
Q3 FY2018CQ1 2018Mar 31, 2018-$7.43M–
Q2 FY2018CQ4 2017Dec 31, 2017-$3.66M–
Q1 FY2018CQ3 2017Sep 30, 2017-$3.70M–
Q4 FY2017CQ2 2017Jun 30, 2017-$3.00M–
Q3 FY2017CQ1 2017Mar 31, 2017-$4.83M–
Q2 FY2017CQ4 2016Dec 31, 2016-$4.17M–
Q1 FY2017CQ3 2016Sep 30, 2016-$5.14M–

More Aytu BioPharma figures

See a number that looks wrong?